Skip to main content

Day: August 11, 2023

Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into early 2025 SEATTLE, Aug. 11, 2023 (GLOBE NEWSWIRE) —  Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Steady progress towards achieving key scientific and business milestones continued during the second quarter, highlighted by our VISTA-targeting KVA12123 clinical program,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “We are pleased with recruitment...

Continue reading

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. Board continues to evaluate strategic alternatives for the Company to maximize shareholder value BOULDER, Colo., Aug. 11, 2023 (GLOBE NEWSWIRE) — Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “Over the past few months, the Board and management have...

Continue reading

Correction: Grant of Incentive Subscription Rights in IDEX Biometrics 11 August 2022 *CORR

The board of directors of IDEX Biometrics ASA resolved on 11 August 2023 to issue 18,566,450 incentive subscription rights to 84 new and continuing employees and individual contractors in the IDEX Biometrics group. The grant was made under the company’s 2023 incentive subscription rights plan as resolved at the annual general meeting on 23 May 2023. The exercise price of the subscription rights is NOK 0.68 per share for 11,166,450 SRs, which SRs vest by 25% per year over four years, and NOK 0.15 per share for 7,400,000 SRs, which SRs vest by 50% per year over two years. The SRs expire on 23 May 2028. Following the grants there are 101,509,226 subscription rights outstanding in IDEX Biometrics. Primary insidersIDEX discloses transactions by the following primary insiders, who were granted incentive subscription rights (SRs) to IDEX...

Continue reading

Proposed changes to Maha’s board of directors and executive management

The nomination committee of Maha Energy AB (publ) (“Maha” or the “Company”) has informed the Company’s board of directors that it intends to propose that an extraordinary general meeting resolves to appoint Paulo Thiago Mendonça as the new chairman of the board of directors. The board of directors has therefore resolved to appoint Kjetil Solbraekke as the new CEO, effective as from the extraordinary general meeting electing Paulo Thiago Mendonça as the chairman of Maha’s board of directors. “The change we are proposing today is in line with our intention to governance Maha to future success. We are strengthening the execution of our management to operate our assets in order to pursue the creation of a cash flow-oriented company with a solid balance sheet and continue our growth strategy,” says Paulo Thiago Mendonça, CEO Maha, and Kjetil...

Continue reading

Nokia Corporation: Repurchase of own shares on 11.08.2023

Nokia CorporationStock Exchange Release11 August 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 11.08.2023 Espoo, Finland – On 11 August 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 336,953 3.55CEUX 44,189 3.55AQEU 2,188 3.53TQEX 6,670 3.57Total 390,000 3.55* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU)...

Continue reading

EURO Ressources reports earnings for the second quarter and six months ended June 30, 2023

  NEWS RELEASE Paris: EUREURO RESSOURCES REPORTS EARNINGS FOR THE SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2023 Paris, France, August 11, 2023: EURO Ressources S.A. (“EURO” or “the Company”) (Paris: EUR) today announced its unaudited statutory interim financial results prepared in accordance with French Generally Accepted Accounting Principles (“GAAP”) and its unaudited condensed interim financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) for the six months ended June 30, 2023. These unaudited interim financial statements were approved by the Board of Directors on August 11, 2023. All financial amounts are expressed in Euros (“€” or “euros”) unless otherwise specified. Highlights Under French GAAP, EURO reported net earnings of €11.0 million (€0.177 per share) for the six months...

Continue reading

Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering

HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 15,544,041 shares of common stock. Each share of common stock was sold together with one common warrant to purchase one share of common stock at a combined offering price of $1.93 and each pre-funded warrant was sold together with one common warrant to purchase one share of common stock...

Continue reading

Ethema Closes on Real Estate Transaction and Eliminates Major Debt

WEST PALM BEACH, FL , Aug. 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Ethema Health Corporation (OTCPINK: GRST) (“Ethema”, “GRST” or the “Company”) filed an 8-K today reporting on the real estate  transaction that closed August 4, 2023 and the history of agreements that led to the final closing.  The net result of all the transactions on the company financial statements will be reflected in part on the Q2 filing and the balance on the Q3 filing.  Mr. Shawn Leon, Company CEO, reported, “The closing of this deal is the result of a lot of hard work and effort and has directly benefited our shareholders.  It is a huge improvement in the overall health of the Company.  We have managed to keep our issued common stock static since March 2, 2022, which was difficult given the large amount of convertible debt we carried throughout that...

Continue reading

Lithium Ionic Files NI 43-101 Technical Report for Mineral Resource Estimate at Bandeira and Outro Lado, Minas Gerais, Brazil

TORONTO, Aug. 11, 2023 (GLOBE NEWSWIRE) — Lithium Ionic Corp. (TSXV: LTH; OTCQB: LTHCF; FSE: H3N) (“Lithium Ionic” or the “Company”) reports that it has filed a technical report, in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”), with respect to an NI 43-101 mineral resource estimate (the “MRE”) for the 100%-owned Itinga Lithium Project (Bandeira and Outro Lado deposits), located in Minas Gerais, Brazil, titled “Mineral Resource Estimate for Lithium Ionic, Itinga Project, near Araçuai Village, Minas Gerais State, Brazil” (the “Technical Report”) and dated August 10, 2023 (with an effective date of June 24, 2023). On June 27, 2023, the Company announced a maiden NI 43-101 compliant mineral resource estimate on its Itinga Lithium Project (the “Project”)...

Continue reading

Platelet-Rich Plasma Market Set to Soar Past USD 2232.54 Billion by 2030

The global Platelet Rich Plasma market size is expected to reach USD 2232.54 billion by 2030 and exhibit a CAGR of 11.15% in the forecast period (2023−2030), according to Skyquest’s latest research report. The healing and tissue regeneration potential, non-invasive nature, minimal risk of adverse reactions, cost-effectiveness, increasing demand for aesthetic and cosmetic procedures, use in various medical specialities, increasing clinical evidence supporting its efficacy, and ability to promote collagen production are fueling the market’s growth. Westford USA, Aug. 11, 2023 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Platelet Rich Plasma market, growing popularity and acceptance in the medical field, increasing research and development activities, integrating PRP with advanced technologies,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.